USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
BIOSENTINEL, LLC
Address:
510 Charmany Drive
Suite 259
Madison, WI
Phone:
N/A
URL:
N/A
EIN:
120254737
DUNS:
199748000
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $949,846.00 3
SBIR Phase II $1,842,045.00 2

Award List:

A Cell-based Assay for Botulinum Neurotoxin Detection and Development

Award Year / Program / Phase:
2009 / SBIR / Phase I
Award Amount:
$587,536.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Botulinum neurotoxins (BoNT) are the most toxic substances known to humans causing respiratory failure upon poisoning. BoNT's lethality and ease of production has led to a category A bioterrorism agent designation for BoNT by the Department of Defense (DoD).… More

SBIR Phase I:De novo assays for detection of the proteolytic activity in botulinum neurotoxin-based pharmaceuticals

Award Year / Program / Phase:
2010 / SBIR / Phase I
Award Amount:
$150,000.00
Agency:
NSF
Principal Investigator:
Abstract:
This Small Business Innovation Research (SBIR) Phase I project proposes to develop a universal, in vitro assay for determining the enzymatic activity of botulinum neurotoxin (BoNT)-based pharmaceuticals. BoNTs are used in many cosmetic and pharmaceutical applications due to their long lasting… More

A Cell-based Assay for Botulinum Neurotoxin Detection and Development

Award Year / Program / Phase:
2011 / SBIR / Phase II
Award Amount:
$1,425,680.00
Agency:
HHS
Principal Investigator:
Ward C. Tucker – 608-441-8172
Abstract:
DESCRIPTION (provided by applicant): Botulinum neurotoxins (BoNTs) are the most toxic substances known to humans, causing respiratory failure. Because of their lethality and ease of production, the Department of Defense (DoD) designates BoNTs as a categoryA bioterrorism agent. Developing effective,… More

Validation of a cell-based assay for BoNT/A detection against the mouse bioassay

Award Year / Program / Phase:
2011 / SBIR / Phase I
Award Amount:
$212,310.00
Agency:
HHS
Principal Investigator:
Ward C. Tucker – 608-441-8172
Abstract:
DESCRIPTION (provided by applicant): Botulinum neurotoxins (BoNT) are the most toxic substances known to humans, causing respiratory failure upon intoxication. Despite their lethality, BoNTs have clinical health and cosmetic applications and are currentlyFDA-approved for treating cervical dystonia,… More

SBIR Phase II: De novo assays for detection of the proteolytic activity in botulinum neurotoxin-based pharmaceuticals

Award Year / Program / Phase:
2012 / SBIR / Phase II
Award Amount:
$416,365.00
Agency:
NSF
Principal Investigator:
Abstract:
This Small Business Innovation Research (SBIR) Phase II project proposes to complete development of a universal, in vitro assay for determining the enzymatic activity of botulinum neurotoxin (BoNT)-based pharmaceuticals. This assay, called BoTest Matrix A Assay, will enable standardized comparisons… More